Insights from "EVER-Vilda", Expert Perspective on Vildagliptin's Applicability in Indian T2DM Patients
The "EVER-Vilda" opinion paper is an Indian expert's evaluation of the efficacy and rationality of vildagliptin. It underscores vildagliptin's versatile applicability, safety and provides practical guidance for healthcare professionals regarding the use of Vildagliptin in T2DM care.
This expert consensus article has been published in the February 2024 issue of the Journal of Clinical Medicine Insights: Endocrinology and Diabetes.
A panel of 25 experts, including endocrinologists, diabetologists, and cardiologists from India, convened for two advisory board meetings to discuss the various roles and combinations of vildagliptin in managing T2DM.
Some of the final consensus statements include:
1. Vildagliptin 100mg SR OD is a practical therapeutic alternative to 50mg IR BID formulation to improve adherence and persistence.
2. Vildagliptin 100mg SR OD dose is equally effective as 50mg twice daily vildagliptin regarding HBA1c, fasting, and postprandial blood glucose levels.
Adapted from:
1. Kalra S, Zargar AH, Sridhar G, et al. Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective. Clinical Medicine Insights: Endocrinology and Diabetes. 2024;17. doi:10.1177/11795514231203911
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.